{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Vandebergh M"],"funding":["NIA NIH HHS","NIMH NIH HHS","NINDS NIH HHS"],"pubmed_abstract":["<h4>Background and objectives</h4><i>TMEM106B</i> has been proposed as a modifier of disease risk in FTLD-TDP, particularly in <i>GRN</i> mutation carriers. Furthermore, <i>TMEM106B</i> has been investigated as a disease modifier in the context of healthy aging and across multiple neurodegenerative diseases. The objective of this study is to evaluate and compare the effect of <i>TMEM106B</i> on gray matter volume and cognition in each of the common genetic FTD groups and in sporadic FTD patients.<h4>Methods</h4>Participants were enrolled through the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study, which includes symptomatic and presymptomatic individuals with a pathogenic mutation in <i>C9orf72, GRN, MAPT, VCP, TBK1, TARDBP</i>, symptomatic non-mutation carriers"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2024.04.05.24305253"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11023674"],"repository":["biostudies-literature"],"pubmed_title":["Gene specific effects on brain volume and cognition of &lt;i&gt;TMEM106B&lt;/i&gt; in frontotemporal lobar degeneration."],"pmcid":["PMC11023674"],"funding_grant_id":["U01 NS100610","R25 NS098999","R21 NS114764","U54 NS092089","U01 NS080818","P30 AG062429","U24 AG021886","R01 AG038791","P30 AG072977","U01 AG045390","U01 AG079850","K23 AG061253","R01 AG062268","R01 MH120794","U19 AG063911"],"pubmed_authors":["Kornak J","Rademakers R","Ramos EM","Grant IM","Clark D","Rosen HJ","Ghoshal N","Onyike C","Litvan I","Domoto-Reilly K","Kwan JY","Petrucelli L","Wynants S","Wint D","Dickerson BC","Pascual B","Gendron TF","Barmada S","Leger GC","Fields JA","Ritter A","Corriveau-Lecavalier N","Irwin D","Tartaglia MC","Galasko DR","Bozoki A","Kolander T","Sullivan AC","Hsiung GR","Van den Broeck M","Geschwind D","Roberson ED","Snyder A","Forsberg LK","Huey ED","Appleby B","Honig LS","Wolf A","Baker MC","Boxer AL","Boeve BF","Pressman P","Darby RR","Borrego-Ecija S","Graff-Radford N","Knopman DS","Vandebergh M","Ramanan VK","Mendez MF","Mester C","Brushaber D","Masdeu JC","Staffaroni AM","Heuer HW","Kantarci K"],"additional_accession":[]},"is_claimable":false,"name":"Gene specific effects on brain volume and cognition of &lt;i&gt;TMEM106B&lt;/i&gt; in frontotemporal lobar degeneration.","description":"<h4>Background and objectives</h4><i>TMEM106B</i> has been proposed as a modifier of disease risk in FTLD-TDP, particularly in <i>GRN</i> mutation carriers. Furthermore, <i>TMEM106B</i> has been investigated as a disease modifier in the context of healthy aging and across multiple neurodegenerative diseases. The objective of this study is to evaluate and compare the effect of <i>TMEM106B</i> on gray matter volume and cognition in each of the common genetic FTD groups and in sporadic FTD patients.<h4>Methods</h4>Participants were enrolled through the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study, which includes symptomatic and presymptomatic individuals with a pathogenic mutation in <i>C9orf72, GRN, MAPT, VCP, TBK1, TARDBP</i>, symptomatic non-mutation carriers","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-11T03:19:44.308Z","creation":"2026-06-11T03:13:00.317Z"},"accession":"S-EPMC11023674","cross_references":{"pubmed":["38633784"],"doi":["10.1101/2024.04.05.24305253"]}}